SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today released the following letter from its Lead Independent Director, James N. Wilson, providing shareholders with an update on recent developments:
Dear Fellow Amylin Shareholder:
As Lead Independent Director of Amylin, I am writing you today to provide a summary of exciting business developments at your company, as well as details on the slate of highly qualified and experienced individuals we nominated to serve on your Board. My fellow Board members and I are committed to transparency and principled corporate governance, and will maintain steady communications with you, our shareholders, in the weeks leading up to our 2009 annual meeting. We are proud of the company we have built, and believe that we have gained momentum to deliver strong results for our shareholders in the near and long term. We strongly believe that the election of our proposed slate of directors at the upcoming annual meeting is critical for Amylin's future success.
Recent Amylin Business Successes
If you have been following the news in recent days, you will have seen that Amylin's long-term strategy is yielding important results. We are beginning to see significant momentum to support our launch of exenatide once weekly. This investigational therapy has the potential to revolutionize the treatment of type 2 diabetes and will be a critical driver of future growth for Amylin. Under the leadership of President and Chief Executive Officer Daniel M. Bradbury and his management team, exenatide once weekly is on track for a planned launch in 2010. The steps that we have taken to enhance the commercial opportunities for our products are already beginning to yield results.
The management team continues to prepare exenati
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved